

ENETS 2021 VIRTUAL

18th Annual ENETS Conference
for the Diagnosis and Treatment
of Neuroendocrine Tumor Disease

25 – 27 February 2021

PRELIMINARY SCIENTIFIC PROGRAMME

Time Zone: Central European Time (CET)

Thursday, 25.02.2021**Welcome****Time:** Thursday 10:45 - 11:00**Speaker:** *Marianne Ellen Pavel, GER***Plenary lecture****Time:** Thursday 11:00 - 11:30**Moderator:** *Marianne Ellen Pavel, GER*

11:00 - 11:30 **Immunotherapy in cancer - How to apply immunotherapy in NET**
Wolf Hervé Fridman, FRA

Pathology of neuroendocrine neoplasms**Time:** Thursday 11:30 - 12:45**Moderator:** *Anne Couvelard, FRA / Marianne Ellen Pavel, GER*

11:30 - 11:45 **New subcategories of NENs: Update on WHO and markers**
Massimo Milione, ITA

11:45 - 12:00 **Spatial and temporal heterogeneity in NET: A clue to understand (naïve and chemoinduced) tumor progression?**
Jerome Cros, FRA

12:00 - 12:15 **Is the molecular transition from NET to NEC-like clinically relevant?**
Halfdan Sorbye, NOR

12:15 - 12:30 **Clinical case discussion**
Jerome Cros, FRA / Halfdan Sorbye, NOR

12:30 - 12:45 **Discussion**

BREAK**Time:** Thursday 12:45 - 13:30**Best abstracts: Clinical science****Time:** Thursday 13:30 - 14:45**Moderator:** *Eva Tiensuu Janson, SWE / Thomas Walter, FRA*

13:30 - 13:40 **Lanreotide as maintenance therapy after first-line treatment in patients with non-resectable duodeno-pancreatic neuroendocrine tumors. An international double-blind, placebo-controlled randomized phase II. Prodiges 31 REMINET. A FFCD study**

13:40 - 13:45 **Q & A**

13:45 - 13:53 **Management of early stage lung carcinoid: Analysis of NCDB database**

13:53 - 13:57 **Q & A**

13:57 - 14:05 **Automatized hepatic tumor volume analysis of neuroendocrine liver metastases by Gd-EOB MRI - A deep learning model to support multidisciplinary cancer conference decision making**

14:05 - 14:09 **Q & A**

- 14:09 - 14:17 **Efficacy, safety and quality of life (QoL) with Lanreotide Autogel (LAN) 120 mg every 14 days in progressive pancreatic or midgut neuroendocrine tumors (NETs): CLARINET FORTE study results**
- 14:17 - 14:21 **Q & A**
- 14:21 - 14:29 **hPG80 (Circulating Progastrin), a novel blood-based biomarker for detection of well differentiated neuroendocrine tumors**
- 14:29 - 14:33 **Q & A**
- 14:33 - 14:41 **Artificial intelligence applications in 68Ga-DOTA PET/CT images: Prediction of response assessment in GEP-NETs undergoing PRRT with 177Lu-DOTATOC**
- 14:41 - 14:45 **Q & A**

Surgery and neoadjuvant therapy in NEN

Time: Thursday 14:45 - 15:45

Moderator: Massimo Falconi, ITA / Eva Tiensuu Janson, SWE

- 14:45 - 15:00 **Pan-NET and Si-NET - Current role of robotic-assisted resections**
Detlef Bartsch, GER
- 15:00 - 15:15 **Pan-NET and Si-NET - How to define locally borderline or not resectable?**
Marie-Pierre Vullierme, FRA
- 15:15 - 15:30 **Pan-NET and Si-NET - Is there a place for downsizing or neoadjuvant therapy in locally borderline or not resectable tumors?**
Stefano Partelli, ITA
- 15:30 - 15:45 **Is there a place for surgery in NEC G3?**
James Howe, USA

BREAK

Time: Thursday 15:45 - 16:00

ENETS / European Society of Endocrinology (ESE)

Time: Thursday 16:00 - 17:15

Moderator: Simona Glasberg, ISR / Beata Kos-Kudła, POL

Swinging between Hormones and NENs: Cutting-edge Developments

- 16:00 - 16:20 **Searching for MEN - Unmet clinical needs and challenges in genetic counselling**
Gerlof Valk, NED
- 16:20 - 16:40 **MTC: Current challenges and unmet needs - New players on the stage**
Mimi I. Hu, USA
- 16:40 - 17:00 **Management of bone involvement in NENs - Whom, when, what, how much?**
Maria Luisa Brandi, ITA
- 17:00 - 17:15 **Discussion**

Closing comments

Time: Thursday 17:15 - 17:30

Speaker: Marianne Ellen Pavel, GER

Satellite Symposium I - Industry-sponsored (Confirmed)

Time: Thursday 17:30 - 19:00

Friday, 26.02.2021

Welcome

Time: Friday 10:45 - 10:55

Speaker: *Marianne Ellen Pavel, GER*

Plenary lecture

Time: Friday 10:55 - 11:25

Moderator: *Dermot O'Toole, IRL*

10:55 - 11:25 **Radiomics in NEN**
Clarisse Dromain, SUI

Nuclear medicine diagnostic and therapy (PARALLEL SESSION)

Time: Friday 11:25 - 12:45

Moderator: *Lisa Bodei, USA / Anders Sundin, SWE*

Functional imaging (11:25 - 12:05)

11:25 - 11:45 **FDG PET for all NET?**
Valentina Ambrosini, ITA / Andreas Kjaer, DEN
Debate: Affirmative speaker/Negative speaker

11:45 - 12:05 **Functional imaging as a predictor of PRRT response: What is robust?**
Vikas Prasad, GER

New approaches to optimise treatments for PRRT (12:05 - 12:45)

12:05 - 12:30 **New tracers and combination and sequential therapies**
Damian Wild, SUI

12:30 - 12:45 **Discussion**

ENETS Nurse & Dietitian Symposium (PARALLEL SESSION)

Time: Friday 11:25 - 12:45

Chair: *Wanda Geilvoet, NED*

11:25 - 11:30 **Welcome & introduction**
Wanda Geilvoet, NED

11:30 - 11:50 **Need to know - A crash course in neuroendocrine tumor imaging**
Anders Sundin, SWE

11:50 - 12:00 **Research - Complementary and alternative medicine in NETs**
Mette Borre, DEN

12:00 - 12:10 **Reach out - How to reach the rare NET-nurses?**
Sophie Noble, GBR

Case studies (12:10 - 12:40)

12:10 - 12:25 **Insulinoma - A complex dilemma**
Deborah Pitfield, GBR

12:25 - 12:40 **Long term NET patient - Thinking outside the box**
Wendy Martin, GBR

12:40 - 12:45 **Closing Comments**
Wanda Geilvoet, NED

BREAK

Time: Friday 12:45 - 13:30

Recent results from clinical trials and key ongoing trials

Time: Friday 13:30 - 15:00

Moderator: Rocio Garcia-Carbonero, ESP / John Ramage, GBR

- 13:30 - 13:50 **Clinical trials design revisited - Future strategies and endpoints**
Simron Singh, CAN
- 13:50 - 14:05 **Clinical trials in Europe**
Enrique Grande, ESP
- 14:05 - 14:20 **Clinical trials in the Americas**
Emily Bergsland, USA
- 14:20 - 14:35 **Clinical trials in Asia and Australia**
Jie Chen, CHN
- 14:35 - 15:00 **Discussion**

BREAK

Time: Friday 15:00 - 15:15

Carcinoid heart disease

Time: Friday 15:15 - 16:15

Moderator: Christos Toumpanakis, GBR / Jerome Zacks, USA

- 15:15 - 15:25 **Value of biomarkers for diagnosis and follow-up**
Stephane Ederhy, FRA
- 15:25 - 15:35 **Optimised therapeutic and perioperative management**
Hans Hofland, NED
- 15:35 - 15:45 **Percutaneous or surgical valve replacement - When is the right time?**
Anders Albåge, SWE
- 15:45 - 15:55 **Challenges in the clinical management of CHD**
Simona Glasberg, ISR
- 15:55 - 16:15 **Discussion**

Best abstracts: Translational research / Basic science (PARALLEL SESSION)

Time: Friday 16:15 - 17:30

Moderator: Justo P. Castaño, ESP / Aurel Perren, SUI

- 16:15 - 16:25 **A patient derived organoid model of neuroendocrine neoplasms enables long term growth in vitro of low grade tumors and reveals therapeutic vulnerabilities**
- 16:25 - 16:30 **Q & A**
- 16:30 - 16:40 **A molecular map of lung neuroendocrine neoplasms**

16:40 - 16:45	Q & A
16:45 - 16:53	Immune heterogeneity and cascade of changes in subtypes of pancreatic neuroendocrine tumors
16:53 - 16:56	Q & A
16:56 - 17:04	Establishment of neuroendocrine neoplasms organoid biobank enables genotype-phenotype mapping
17:04 - 17:07	Q & A
17:07 - 17:15	Transcriptomic deconvolution of neuroendocrine neoplasms predicts clinically relevant characteristics
17:15 - 17:18	Q & A
17:18 - 17:26	Splicing machinery dysregulation in low grade pulmonary carcinoids
17:26 - 17:29	Q & A
17:29 - 17:30	Closing comments

INCA/ENETS Symposium - Patient impact on improving NET research and time to diagnosis (PARALLEL SESSION)

Time: Friday 16:15 - 17:30

Chairs: Catherine Bouvier, GBR / Marianne Ellen Pavel, GER

16:15 - 16:20	Welcome and introductions from ENETS and INCA <i>Catherine Bouvier, GBR / Marianne Ellen Pavel, GER</i>
---------------	---

Part 1: Improving NET research (16:20 - 16:50)

16:20 - 16:23	Setting the scene: Why is patient-led/driven research instrumental? <i>Teodora Kolarova, BUL</i>
---------------	--

16:23 - 16:50 Best practice examples of patient involvement in research

16:23 - 16:30	SCAN <i>Mark McDonnell, IRL</i>
---------------	---

16:30 - 16:35	INCA boot camp for research advocates <i>Jackie Herman, CAN</i>
---------------	---

16:35 - 16:40	Cell Line Project - Tumor tissue donation to facilitate research <i>Elyse Gellerman, USA</i>
---------------	--

16:40 - 16:50	The value of patient-driven research <i>Jaume Capdevila, ESP</i>
---------------	--

Part 2: Improving time to diagnosis (16:50 - 17:25)

16:50 - 16:58	Early diagnosis challenges as reported in SCAN & SCAN II launch <i>Sugandha Dureja, IND</i>
---------------	---

16:58 - 17:05	Impact of misdiagnosis on healthcare systems and patients - Understanding the barriers to early diagnosis <i>Catherine Bouvier, GBR</i>
---------------	---

17:05 - 17:10	Optimal care pathway for NETs <i>Simone Leyden, AUS</i>
---------------	---

17:10 - 17:20 **NEN misdiagnosis and late diagnosis - How can we have a positive impact on changing the facts?**
Dermot O'Toole, IRL

17:20 - 17:25 **Questions & answers**

17:25 - 17:30 **Take home messages and closing comments**
Catherine Bouvier, GBR / Marianne Ellen Pavel, GER

Closing comments

Time: Friday 17:30 - 17:45

Speaker: *Marianne Ellen Pavel, GER*

Satellite Symposium II - Industry-sponsored (Confirmed)

Time: Friday 17:45 - 19:15

Saturday, 27.02.2021**Welcome****Time:** Saturday 10:45 - 10:50**Speaker:** *Marianne Ellen Pavel, GER***Treatment outcomes****Time:** Saturday 10:50 - 11:50**Moderator:** *Antongiulio Faggiano, ITA / Anja Rinke, GER*

- 10:50 - 11:05 **Psychological aspects - Basic conditions and impact of therapy in carcinoid syndrome**
John Ramage, GBR
- 11:05 - 11:20 **Treatment outcome in NEN patients based on gender**
Pamela Kunz, USA
- 11:20 - 11:35 **Treatment outcome in NEN patients with diabetes - Basic conditions and impact of therapy**
Sara Pusceddu, ITA
- 11:35 - 11:50 **Discussion**

Challenges and controversies (ENETS / NextGEN ENETS)**Time:** Saturday 11:50 - 12:50**Moderator:** *Philippe Ruszniewski, FRA / Juan Valle, GBR*

- 11:50 - 12:05 **Where is the place for radiotherapy in the management of NEN?**
David Chan, AUS
- 12:05 - 12:20 **NET and pregnancy/fertility**
Angela Lamarca, GBR
- 12:20 - 12:35 **Intra-abdominal complications of NET (occlusion, peritoneal, carcinomatosis, fibrosis, ischemia) - How to prevent and how to treat?**
Marc Peeters, BEL
- 12:35 - 12:50 **Effects on investigations and therapy during COVID pandemic**
Nicola Fazio, ITA

Satellite Symposium III - Industry-sponsored (Optional)**Time:** Saturday 12:50 - 13:50**Pulmonary NET****Time:** Saturday 13:50 - 15:05**Moderator:** *Eric Baudin, FRA*

- 13:50 - 14:00 **Limitations of the new WHO classification**
Aurelie Fabre, IRL
- 14:00 - 14:10 **Bronchial-NEN - What is the adequate extent of resection?**
Pier Luigi Filosso, ITA
- 14:10 - 14:20 **Who should receive adjuvant therapy or therapy for residual disease?**
Debashis Sarker, GBR
- 14:20 - 14:35 **Systemic therapy of lung carcinoids**
Eric Baudin, FRA

- 14:35 - 14:45 **Is there a place for immunotherapy in lung NEN?**
Jaume Capdevila, ESP
- 14:45 - 15:05 **Discussion**

BREAK

Time: Saturday 15:05 - 15:20

What's new?

Time: Saturday 15:20 - 16:20

Moderator: *Eric Baudin, FRA / Elisabeth Nieveen van Dijkum, NED*

- 15:20 - 15:50 **Translational NET update - Review of the year**
Justo P. Castaño, ESP
- 15:50 - 16:20 **ENETS abstracts highlights**
Nicholas Simon Reed, GBR

Awards Ceremony - Best abstracts 2021

Time: Saturday 16:20 - 16:35

Moderator: *Marianne Ellen Pavel, GER / Nicholas Simon Reed, GBR*

Closing comments

Time: Saturday 16:35 - 16:45

Speaker: *Marianne Ellen Pavel, GER*

European Neuroendocrine Tumor Society e.V. (ENETS)

Langenbeck-Virchow-Haus
Luisenstr. 58/59
10117 Berlin

VAT Nr.: DE252810143

Amtsgericht Charlottenburg: VR 23838 B

www.enets.org | info@enets.org